Last reviewed · How we verify
BMS-247550
At a glance
| Generic name | BMS-247550 |
|---|---|
| Also known as | epothilone derivative, ixabepilone, Ixempra® |
| Sponsor | SWOG Cancer Research Network |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. (PHASE2)
- Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy (PHASE2)
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (PHASE2)
- Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer (PHASE1, PHASE2)
- Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
- Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab (PHASE2)
- BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-247550 CI brief — competitive landscape report
- BMS-247550 updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI